Table 4.
AP+ FFU per ml for plasmid combination: | ||||||
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
pLadeno5 | + | + | + | |||
pMTrep6 | + | − | − | |||
Amount | pCMVcap6 | − | + | − | ||
AAV Vector | cap plasmid | (vg) | pARAP4 | + | + | + |
ACZn | CMVcap6 | 7 × 1010 | 9 × 104 | 5.3 × 102 | 0 | 0 |
Captron | 7 × 1010 | 1 × 105 | 2 | 1 | 1 | |
None | None | 6 × 104 | 0 | 0 | 0 | |
ACMVcFIX | CMVcap6 | 7 × 1010 | 1.6 × 105 | 2.8 × 103 | 3 | 3 |
Captron | 7 × 1010 | 1.9 × 105 | 3 | 1 | 3 | |
None | None | 2.2 × 105 | 2 | 3 | 1 | |
ACF3’B | CMVcap6 | 3.8 × 1011 | ND | 41 | 0 | 0 |
Captron | 3.8 × 1011 | ND | 0 | 3 | 3 | |
The cap and rep complementation assay was performed as shown in Figure 1 and described in Materials and Methods, except that the crude cell lysate was filtered (0.2 µm-pore-size) to reduce background AP. Results are means from one experiment done in duplicate (ACZn and ACF3’B) and means from two, five or four experiments done in duplicate (ACMVcFIX made with the CMVcap6 plasmid, the captron plasmid or none, respectively). ND, not done.